

Tocilizumab for Acute Chest Syndrome

NCT05640271

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Chicago
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (2)

- Adults ≥ 12 years of age
- Prior diagnosis of sickle cell disease (Hb SS, Hb SC, Hb Sβ+, and Hb Sβ0)

Exclusion (12)

- Pregnant patients or breastfeeding mothers.
- Prior treatment with gene therapy or a stem cell transplant.
- Current enrollment in a clinical trial involving an FDA-regulated drug or biologic.
- Current neutropenia (absolute neutrophil count $\leq 1000/\text{mm}^3$)
- Current thrombocytopenia (platelet count $\leq 50,000/\text{mm}^3$)
- ... and 7 more (see full listing online)

Locations (1 total)

University of Chicago, Chicago, Illinois, United States